Dichotomy in Neutralizing Antibody Induction to Peptide-Conjugated Vaccine in Squalene Emulsion Contrast With Aluminum Hydroxide Formulation.
B-cells
adjuvant
neutralizing
squalene
vaccine
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
01
2022
accepted:
22
02
2022
entrez:
25
4
2022
pubmed:
26
4
2022
medline:
27
4
2022
Statut:
epublish
Résumé
W614A-3S peptide is a modified 3S motif of the HIV-gp41 (mutation W614A). We previously detected the presence of natural neutralizing antibodies directed against W614A-3S peptide (NAbs) in long-term non-progressor HIV
Identifiants
pubmed: 35464449
doi: 10.3389/fimmu.2022.848571
pmc: PMC9021396
doi:
Substances chimiques
Adjuvants, Immunologic
0
Antibodies, Neutralizing
0
Broadly Neutralizing Antibodies
0
Emulsions
0
Peptides
0
Vaccines, Conjugate
0
Vaccines, Subunit
0
Aluminum Hydroxide
5QB0T2IUN0
Squalene
7QWM220FJH
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
848571Informations de copyright
Copyright © 2022 Bonduelle, Chaudesaigues, Tolazzi, Suleiman, de Bernard, Alves, Nourikyan, Bohec, Baudrin, Katinger, Debré, Scarlatti, Vieillard and Combadière.
Déclaration de conflit d'intérêts
VV is a member of the scientific advisory board of Minka Therapeutics. ES and DK were employed by Polymun Scientific Immunbiologische Forschung GmbH. SB, KA, and JN were employed by Altrabio. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Hum Vaccin Immunother. 2016;12(1):226-30
pubmed: 26619353
J Immunol. 2015 Aug 15;195(4):1617-27
pubmed: 26170383
EBioMedicine. 2017 Aug;22:122-132
pubmed: 28712768
Nat Immunol. 2015 Mar;16(3):296-305
pubmed: 25642821
Science. 2017 May 19;356(6339):
pubmed: 28408722
Pathogens. 2021 Mar 17;10(3):
pubmed: 33802803
Sci Rep. 2021 Apr 26;11(1):8993
pubmed: 33903642
Cell Mol Life Sci. 2012 May;69(9):1435-45
pubmed: 22045557
PLoS Pathog. 2018 Feb 23;14(2):e1006913
pubmed: 29474444
J Immunol Res. 2019 Mar 24;2019:9804584
pubmed: 31019982
Nat Rev Immunol. 2004 Mar;4(3):199-210
pubmed: 15039757
Biologicals. 2011 Jul;39(4):195-204
pubmed: 21715186
J Exp Med. 2016 May 30;213(6):1095-111
pubmed: 27217539
Annu Rev Immunol. 2010;28:413-44
pubmed: 20192810
Cell. 2019 May 16;177(5):1153-1171.e28
pubmed: 31080066
J Immunol. 1998 May 15;160(10):4688-95
pubmed: 9590214
Nat Immunol. 2015 Jun;16(6):663-73
pubmed: 25894659
Proc Natl Acad Sci U S A. 2009 May 12;106(19):7962-7
pubmed: 19416838
Immunity. 2017 Dec 19;47(6):1142-1153.e4
pubmed: 29262350
Immunity. 2012 Sep 21;37(3):412-25
pubmed: 22999947
Immunity. 2014 May 15;40(5):657-68
pubmed: 24768347
J Exp Med. 1997 Aug 4;186(3):439-48
pubmed: 9236196
Nature. 2009 Apr 2;458(7238):636-40
pubmed: 19287373
Clin Infect Dis. 2013 Sep;57(5):745-55
pubmed: 23696512
Front Immunol. 2020 Sep 23;11:579761
pubmed: 33072125
Vaccines (Basel). 2014 Jul 02;2(3):515-36
pubmed: 26344743
J Infect Dis. 1997 Oct;176(4):924-32
pubmed: 9333150
Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):10981-6
pubmed: 16046540
J Virol. 2014 Mar;88(5):2489-507
pubmed: 24352443
Curr Opin Immunol. 2010 Jun;22(3):411-6
pubmed: 20466528
PLoS One. 2012;7(5):e36438
pubmed: 22590544
Nat Rev Drug Discov. 2007 May;6(5):404-14
pubmed: 17473845
Appl Environ Microbiol. 1983 Sep;46(3):560-4
pubmed: 6416165
Nat Med. 2018 Jun;24(6):857-867
pubmed: 29867235
Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11628-32
pubmed: 8524817
Vaccines (Basel). 2019 Sep 02;7(3):
pubmed: 31480779
J Mol Recognit. 2006 May-Jun;19(3):183-7
pubmed: 16680720